安罗替尼靶向疗法对非小细胞肺癌患者免疫功能及CYFRA21-1和CEA的影响

摘要/Abstract

摘要： 目的探讨与分析安罗替尼靶向疗法对非小细胞肺癌患者免疫功能及细胞角蛋白19片段（CYFRA21-1）和癌胚抗原（CEA）的影响。方法选取2019年1月—2020年6月在汕头大学医学院附属肿瘤医院诊治的非小细胞肺癌患者87例作为研究对象,根据随机数表法把患者分为安罗替尼组（44例）与对照组（43例）。对照组给予放疗治疗,安罗替尼组在对照组治疗的基础上给予安罗替尼治疗,两组均治疗观察4周,检测患者的免疫功能治疗效果、不良反应、及CYFRA21-1、CEA表达变化情况。结果治疗后安罗替尼组的总有效率明显高于对照组,差异有统计学意义（P<0.05）。安罗替尼组放疗期间的放射性肺炎、放射性食管炎的发生率稍低于对照组,差异无统计学意义（P>0.05）。安罗替尼组治疗后的CD3⁺T淋巴细胞比例、CD4⁺T淋巴细胞比例明显高于治疗前（P<0.05）,安罗替尼组也明显高于对照组,差异有统计学意义（P<0.05）。安罗替尼组治疗后的血清CYFRA21-1和CEA含量明显低于治疗前（P<0.05）,安罗替尼组也明显低于对照组,差异有统计学意义（P<0.05）。结论安罗替尼靶向疗法联合放疗在非小细胞肺癌患者的应用能有效抑制血清CYFRA21-1和CEA的表达,提高患者的免疫功能,能有效提高治疗效果。

关键词: 安罗替尼, 靶向疗法, 放疗, 非小细胞肺癌, 免疫功能

Abstract: Objective To investigate and analysis the effects of anlotinib targeted therapy on immune function and CYFRA21-1 and CEA in patients with non-small cell lung cancer. Methods From January 2019 to June 2020, a total of 87 cases of patients with non-small cell lung cancer who were diagnosed and treated in the Cancer Hospital Affiliated to Shantou University School of Medicine were selected as the research subjects. The patients were divided into anlotinib group of 44 cases and control group group of 43 cases according to the treatment methods. The control group were given radiotherapy, and the anlotinib group were given anlotinib based on the treatment of the control group. Both groups were treated for 4 weeks, and the immune function and the changes of CYFRA21-1 and CEA expression were detected. Results After treatment, the total effective rate of the anlotinib group was significantly higher than that of the control group, and the difference were statistically significant (P<0.05). The incidence rates of radiation pneumonitis and radiation esophagitis during radiotherapy in the anlotinib group was slightly lower than the control group, and the comparison was not statistically significant (P>0.05). The proportion of CD3⁺T lymphocytes and CD4⁺T lymphocytes in the anlotinib group after treatment were significantly higher than those before treatment (P<0.05), and the proportions of the two T lymphocytes of the anlotinib group were also significantly higher than those in the control group, and the differences were statistically significant (P<0.05). The serum CYFRA21-1 and CEA levels in the anlotinib group after treatment were significantly lower than those before treatment (P<0.05), and the levels of serum CYFRA21-1 and CEA in anlotinib group were also significantly lower than those in the control group, and the differences were statistically significant (P<0.05). Conclusion The application of anlotinib targeted therapy combined with radiotherapy in patients with non-small cell lung cancer can effectively inhibit the expression of serum CYFRA21-1 and CEA, improve the immune function of patients, effectively improve the treatment effect.

Key words: anlotinib, targeted therapy, radiotherapy, non-small cell lung cancer, immune function

中图分类号:

R734.2

郭岱年, 方翎, 徐俊, 林菲. 安罗替尼靶向疗法对非小细胞肺癌患者免疫功能及CYFRA21-1和CEA的影响[J]. 中华养生保健, 2023, 41(9): 47-50.

GUO Dainian, FANG Ling, XU Jun, LIN Fei. Effect of Anlotinib Targeted Therapy on Immune Function and CYFRA21-1 and CEA in Patients With Non-small Cell Lung Cancer[J]. ZHONGHUA YANGSHENG BAOJIAN, 2023, 41(9): 47-50.

参考文献

[1] 施阳阳,李延文.安罗替尼三线治疗广泛期小细胞肺癌疗效分析[J].现代肿瘤医学,2022,30(4):618-621.
[2] 王宁军,高业博,马银杰,等.小细胞肺癌经安罗替尼治疗后的特殊影像学评价[J].重庆医学,2022,51(1):41-44,49.
[3] 王伟,李鹏飞,马鹏飞,等.安罗替尼联合多西他赛治疗晚期非小细胞肺癌的近期疗效及对远期生存和不良反应的影响[J].癌症进展,2022,20(2):181-183.
[4] 王亚,李心忠,姜松龄,等.安罗替尼联合替吉奥二线后治疗晚期非小细胞肺癌的临床疗效[J].安徽医学,2022,43(1):36-40.
[5] XU B, YAN M, MA F, et al.Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial[J]. PLancet Oncol,2021,22(3):351-360.
[6] 王玲,杜倩宇,王西勇.安罗替尼联合化疗治疗驱动基因阴性晚期非小细胞肺癌的疗效及对血清VEGF、bFGF、MMP-9水平的影响[J].临床和实验医学杂志,2022,21(1):39-43.
[7] 宋云,冷朝辉.安罗替尼靶向治疗对人表皮生长因子受体阳性晚期非小细胞肺癌患者疾病控制率的影响[J].药品评价,2022,19(2):100-102.
[8] 张帅. 常规化疗联合安罗替尼治疗NSCLC的疗效及对患者MALAT1、VEGF及预后的影响[J].实用癌症杂志,2022,37(1):80-82.
[9] 侯佳林,李龙.抗血管生成药物治疗非小细胞肺癌的研究进展[J].山东医药,2022,62(7):97-101.
[10] 中华医学会病理学分会, 国家病理质控中心, 中华医学会肿瘤学分会肺癌学组,等. 非小细胞肺癌分子病理检测临床实践指南(2021版)[J]. 中华病理学杂志,2021,50(4):323-332.
[11] 盛晓安,汪超,肖鑫,等.安罗替尼联合化疗对二线化疗失败晚期非小细胞肺癌的疗效分析[J].国际肿瘤学杂志,2022,49(3):134-139.
[12] 雷立锋,李雪,胡会杰.不同分期肺癌患者血清中PDCD5蛋白、CEA和CYFRA21-1表达水平变化及临床意义[J].实用癌症杂志,2022,37(1):25-28.
[13] 卢春青,王盼,韩晓蓓,等.非小细胞肺癌脑转移危险因素评估及意义[J].临床检验杂志,2022,40(2):141-146.
[14] 方丽兰,余更生,庞景灼,等.非小细胞肺癌患者外周血循环肿瘤细胞与临床病理特征和血清CEA、NSE、Cyfra21-1、pro-GRP的关系分析[J].现代生物医学进展,2022,22(3):510-514.
[15] 马蕾,许靖,赵凤德,等.血清细胞角蛋白19片段、鳞状细胞癌抗原、肿瘤相关抗原联合检测对肺炎型肺癌的诊断价值分析[J].中国医刊,2022,57(2):153-156.
[16] MA F, OUYANG Q, LI W, et al.Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study[J]. J Clin Oncol,2019,37(29):2610-2619.
[17] 张瑞,张民杰,张远航.调强放疗与三维适形放疗治疗局部晚期非小细胞肺癌的对比研究[J].临床医学,2022,42(1):8-10.
[18] 陈礼昌,滕凤猛.血清肿瘤标志物在肺癌不同病理分型中的应用价值[J].临床误诊误治,2022,35(1):29-32,47.
[19] 樊化,孙萍,巫开文,等.CT联合血清CEA、NSE、Cyfra21-1对非小细胞肺癌纵隔淋巴结转移的预测价值[J].山东医药,2022,62(7):57-60.